Combination therapy for colorectal cancer with specific gene change
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three drugs (doxorubicin liposome, capecitabine, oxaliplatin) plus a targeted therapy called bevacizumab for people with advanced colorectal cancer that has a specific genetic change (SMAD4 R361H/C). The goal is to see if this combination can shrink tumors and slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with colorectal cancer that cannot be removed with surgery.
- If your tumor is on the left side or in the rectum, it must not have the normal (wild-type) RAS gene.
- Your tumor must have a specific change (mutation) called SMAD4 R361H/C.
- You have not had chemotherapy before.
- You are generally active and able to care for yourself (performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of focused radiation (SBRT), chemotherapy (CAPEOX), and two targeted drugs (bevacizumab and an immunotherapy) for colorectal cancer that has spread and can't be removed by surgery. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
This study tests a new combination treatment for advanced colorectal cancer that has stopped responding to standard treatments or is newly diagnosed. It aims to see if the combination can shrink tumors or slow their growth.
Hear when a new Advanced Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.